Algeta oversubscribed on $80m growth deal
Norwegian cancer drug firm Algeta launched a Nkr390m-Nkr470m ($67m-$82m) bookbuild on Monday evening in a capital raise to build up its US sales operation and to fund research and development, while one of its leading shareholders sells down a small portion of its holding.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: